Is Use of Bone-Morphogenetic Proteins for Spine Fusion Surgery Cost-effective?

Share this story with your network

Prevalence, Complications, and Hospital Charges Associated With Use of Bone-Morphogenetic Proteins in Spinal Fusion Procedures

Kevin S. Cahill, MD, PhD, MPH; John H. Chi, MD, MPH; Arthur Day, MD; Elizabeth B. Claus, MD, PhD

Context: No national data exist to examine use of bone-morphogenetic proteins (BMPs) in spinal fusion surgery.

Objective: To determine the patterns of use and rates of complications and financial charges associated with BMP use in spinal fusion nationally.

Design, Setting, and Patients: Retrospective cohort study of 328 468 patients undergoing spinal fusion procedures from 2002-2006 identified from the Nationwide Inpatient Sample database, a 20% sample of US community hospitals.

Main Outcome Measures: The rates of use of BMP among patients undergoing spinal fusion procedures are examined along with complications, length of stay, and hospital charges associated with use of this fusion adjunct.

Leave a Comment

Your email address will not be published. Required fields are marked *